<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Long-term survivors of <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) have a high incidence of clonal disorders, in particular <z:hpo ids='HP_0004818'>paroxysmal nocturnal hemoglobinuria</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e>), <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), and <z:hpo ids='HP_0011009'>acute</z:hpo> nonlymphocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>To investigate the potential involvement of N-<z:mp ids='MP_0011356'>RAS</z:mp> gene mutations in the predisposition to leukemic evolution, a subset of patients at potentially increased risk for clonal disease was selected based on evidence of existing <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Nine patients showed a monoclonal pattern of X-chromosome inactivation, 18 demonstrated a <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> clone, and in 3 MDS developed during the course of this study </plain></SENT>
<SENT sid="3" pm="."><plain>No mutations were detected during the aplastic phase of disease; 2 of 3 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> after AA also showed no mutations </plain></SENT>
<SENT sid="4" pm="."><plain>However, in 1 patient in whom the disease transformed from AA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, a mutation of GGT --&gt; GAT at N-<z:mp ids='MP_0011356'>RAS</z:mp> codon 13 became detectable, whereas the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> mutation disappeared </plain></SENT>
<SENT sid="5" pm="."><plain>The authors conclude that N-<z:mp ids='MP_0011356'>RAS</z:mp> mutations are not an early event preceding transformation of AA or AA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> to <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>In a subset of patients, <z:mp ids='MP_0011356'>RAS</z:mp> mutations may occur at the time of evolution to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, but preexisting <z:mp ids='MP_0011356'>RAS</z:mp> mutations do not explain the propensity of AA to <z:e sem="disease" ids="C0598766" disease_type="Neoplastic Process" abbrv="">leukemogenesis</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Although <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> is also associated with <z:hpo ids='HP_0001909'>leukemia</z:hpo>, this may arise in the non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PNH</z:e> cells, indicating that PIG-A gene mutation is not per se oncogenic </plain></SENT>
<SENT sid="8" pm="."><plain>(Blood </plain></SENT>
<SENT sid="9" pm="."><plain>2000;95:646-650) </plain></SENT>
</text></document>